

MEDIA RELEASE

Cordlife launches proprietary lifestyle genetic screening services in Indonesia

- Cordlife Indonesia to expand its diagnostic offerings through the launch of lifestyle genetic screening tests developed by the Group's diagnostics team based in Hong Kong.
- The lifestyle genetic screening services will include Diet, Health, Sports, and Skin panels that can provide individuals with personalised insights into their genetic makeup and how it may impact various aspects of their well-being.
- The launch is in line with the Group's strategy of expanding the scale and scope of its product and service offerings to meet the needs of three generations of a family.

SINGAPORE, 10 July 2023 – Cordlife Group Limited ("**Cordlife**", together with its subsidiaries, the "**Group**"), a Singapore Exchange mainboard listed company, is pleased to announce the launch of its proprietary lifestyle genetic screening services in Indonesia. Developed in-house by Cordlife's Hong Kong-based diagnostic team, these screening services encompass Diet, Health, Sports, and Skin genetic screening, offering personalised insights to individuals seeking to optimise their well-being and improve their lifestyles.

The launch of these services into the Indonesian market is a strategic move by Cordlife to diversify its product and service offerings on a larger scale and scope. With the growing interest in personalised healthcare and genetic insights, offering these services aligns with the Group's commitment to helping people live, healthier, happier, and longer.

Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife Group Limited commented, "The growing need to understand one's disposition demonstrates the benefits of lifestyle screening tests. By leveraging our in-house diagnostic expertise and advanced genetic technologies, we provide individuals with the opportunity to unlock the power of their genetic information to make informed choices for their diet, skincare, fitness, and overall health. This launch marks an important milestone in our ongoing commitment to expanding our product and service portfolio to better serve our clients."

Individuals can gain access to personalised insights based on their unique genetic makeup using Cordlife's lifestyle genetic screening services.

- **Cordlife DIET** offers tailored recommendations for optimising nutrient intake, weight management, and dietary modifications, giving individuals greater control over achieving their goals.



- **Cordlife HEALTH** empowers individuals with information about their genetic predispositions to various health conditions, allowing them to take proactive preventive measures and develop personalised plans for their healthcare.
- **Cordlife SKIN** analyses an individual's genetic variation and assesses risk for seven of the most common manifestations, including acne, tanning, and inflammation.
- **Cordlife SPORTS** gives athletes and fitness enthusiasts information about their athletic performance potential, exercise responsiveness, and risk of injury, enabling them to create customised training regimes and injury prevention strategies.

These tests are non-invasive and can be done at home with just one saliva swab. The results of these personalised tests have far-reaching benefits and may be instrumental in enhancing the overall outcome of everyday activities related to healthcare, wellness, skincare, and fitness.

Visit <https://biotech.cordlife.co.id/genetic-tests/> for more information on Cordlife's lifestyle genetic screening services, available in Hong Kong and Indonesia.

End

ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group"), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia's largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia, and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, cord tissue and lenticule banking, Cordlife offers families a comprehensive suite of diagnostics services, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening.

Two of Cordlife's primary focus areas are providing reliable quality and being customer-centric. All of the Group's facilities are accredited by the Association for the Advancement of Blood & Biotherapies ("AABB"), an organisation dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available, and effective worldwide. Furthermore, Cordlife Singapore and Healthbaby Hong Kong are the only two private cord blood banks in Asia and five worldwide to be accredited by both AABB and the Foundation for the Accreditation of Cellular Therapy ("FACT"), another world-class accreditation body for cord blood banks worldwide. In the area of clinical diagnostics, Cordlife India and Healthbaby Hong Kong are both accredited by the College of American Pathologists ("CAP"). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies, and



Cordlife India one of the only two medical laboratories in West Bengal to be holding accreditations from the National Accreditation Board for Testing and Calibration Laboratories ("NABL") and CAP. These quality achievements reinforce the Group's commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Kamal Samuel
Ms Urvija Diwan

OFFICE : (65) 9272 1071

EMAIL : kamal@financialpr.com.sg
urvija@financialpr.com.sg